What is Pure Bioscience Inc's earnings per share (EPS)?

Pure Bioscience Inc (PURE) reported diluted earnings per share of $-0.02 for fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pure Bioscience Inc Financials

PURE

Source SEC Filings (10-K/10-Q) Updated Mar 16, 2026 Currency USD FYE July

This page shows Pure Bioscience Inc (PURE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Pure Bioscience Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, Pure Bioscience Inc generates $0.84 in operating cash flow (-$2.0M OCF vs -$2.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-7.9x

Pure Bioscience Inc earns $-7.9 in operating income for every $1 of interest expense (-$2.3M vs $287K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.2M

YoY+12.4%

5Y CAGR-20.5%

10Y CAGR+11.7%

Pure Bioscience Inc generated $2.2M in revenue in fiscal year 2025. This represents an increase of 12.4% from the prior year.

EBITDA

-$2.3M

YoY+25.4%

Pure Bioscience Inc's EBITDA was -$2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.4% from the prior year.

Net Income

-$2.4M

YoY+28.4%

Pure Bioscience Inc reported -$2.4M in net income in fiscal year 2025. This represents an increase of 28.4% from the prior year.

EPS (Diluted)

$-0.02

YoY+33.3%

Pure Bioscience Inc earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$434K

YoY+25.4%

5Y CAGR-34.0%

10Y CAGR-23.2%

Pure Bioscience Inc held $434K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

112M

YoY+0.0%

5Y CAGR+5.1%

10Y CAGR+7.3%

Pure Bioscience Inc had 112M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

59.3%

YoY+0.3pp

5Y CAGR+1.1pp

10Y CAGR-1.6pp

Pure Bioscience Inc's gross margin was 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.

Operating Margin

-103.4%

YoY+59.9pp

5Y CAGR-103.4pp

10Y CAGR+944.6pp

Pure Bioscience Inc's operating margin was -103.4% in fiscal year 2025, reflecting core business profitability. This is up 59.9 percentage points from the prior year.

Net Margin

-109.1%

YoY+62.2pp

5Y CAGR-109.2pp

10Y CAGR+937.1pp

Pure Bioscience Inc's net profit margin was -109.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 62.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$316K

YoY+4.6%

5Y CAGR-0.4%

10Y CAGR-8.8%

Pure Bioscience Inc invested $316K in research and development in fiscal year 2025. This represents an increase of 4.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

PURE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.2M+12.4%	$2.0M+4.5%	$1.9M+3.2%	$1.8M-51.0%	$3.7M-46.5%	$6.9M
Cost of Revenue	$899K+10.9%	$811K-10.5%	$906K+6.2%	$853K-53.9%	$1.9M-36.0%	$2.9M
Gross Profit	$1.3M+13.1%	$1.2M+18.6%	$971K-2.9%	$1.0M-51.8%	$2.1M-48.4%	$4.0M
R&D Expenses	$316K+4.6%	$302K+1.7%	$297K-6.9%	$319K-5.9%	$339K+5.3%	$322K
SG&A Expenses	$3.3M-18.1%	$4.0M-7.5%	$4.3M+6.2%	$4.1M+0.1%	$4.0M+9.5%	$3.7M
Operating Income	-$2.3M+28.8%	-$3.2M+19.1%	-$3.9M-5.9%	-$3.7M-61.1%	-$2.3M-57875.0%	$4K
Interest Expense	$287K+100.7%	$143K+921.4%	$14K+133.3%	$6K+50.0%	$4K-20.0%	$5K
Income Tax	$0	$0	$0-100.0%	$2K0.0%	$2K0.0%	$2K
Net Income	-$2.4M+28.4%	-$3.4M+15.4%	-$4.0M-13.5%	-$3.5M-50.5%	-$2.3M-58075.0%	$4K
EPS (Diluted)	$-0.02+33.3%	$-0.03+25.0%	$-0.040.0%	$-0.04-33.3%	$-0.03	$0.00

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$1.1M+156.4%	$443K-37.3%	$707K-7.3%	$763K+56.0%	$489K+25.1%	$391K-29.5%	$555K+17.6%	$472K
Cost of Revenue	$464K+125.2%	$206K-20.2%	$258K-12.8%	$296K+42.3%	$208K+26.8%	$164K-29.0%	$231K+16.1%	$199K
Gross Profit	$688K+189.1%	$238K-47.1%	$450K-3.8%	$468K+65.4%	$283K+24.7%	$227K-30.2%	$325K+18.2%	$275K
R&D Expenses	$160K+116.2%	$74K-14.0%	$86K+17.8%	$73K-19.8%	$91K+12.3%	$81K+14.1%	$71K+2.9%	$69K
SG&A Expenses	$1.6M+87.7%	$847K+14.0%	$743K+1.6%	$731K-5.8%	$776K-10.9%	$871K-1.1%	$881K+4.3%	$845K
Operating Income	-$1.1M-55.5%	-$683K-80.2%	-$379K-12.8%	-$336K+42.5%	-$584K+19.4%	-$725K-15.6%	-$627K+10.3%	-$699K
Interest Expense	$190K+88.1%	$101K+11.0%	$91K+15.2%	$79K+1.3%	$78K+11.4%	$70K+16.7%	$60K+50.0%	$40K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M-59.1%	-$785K-69.2%	-$464K-39.8%	-$332K+42.8%	-$580K+27.3%	-$798K-15.8%	-$689K+8.9%	-$756K
EPS (Diluted)	$-0.010.0%	$-0.01	$0.00	N/A	$-0.010.0%	$-0.010.0%	$-0.01	N/A

PURE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.2M+28.4%	$924K-58.9%	$2.3M-39.2%	$3.7M+4.1%	$3.6M-38.3%	$5.8M
Current Assets	$1.2M+29.1%	$911K-55.9%	$2.1M-32.7%	$3.1M+25.2%	$2.5M-49.7%	$4.9M
Cash & Equivalents	$434K+25.4%	$346K-76.0%	$1.4M-41.3%	$2.5M+39.3%	$1.8M-49.2%	$3.5M
Inventory	$237K+229.2%	$72K-30.8%	$104K-56.5%	$239K-23.4%	$312K-57.4%	$733K
Accounts Receivable	$389K+4.9%	$371K+6.9%	$347K+37.7%	$252K+5.9%	$238K-57.5%	$560K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M+52.3%	$4.4M+67.9%	$2.6M+276.7%	$699K-15.6%	$828K-8.6%	$906K
Current Liabilities	$3.2M+246.8%	$911K+13.0%	$806K+15.3%	$699K-15.6%	$828K-8.6%	$906K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$5.5M-58.6%	-$3.5M-812.8%	-$383K-112.8%	$3.0M+10.0%	$2.7M-43.9%	$4.9M
Retained Earnings	-$139.5M-1.6%	-$137.3M-2.5%	-$134.0M-2.8%	-$130.3M-2.9%	-$126.6M-2.4%	-$123.7M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	N/A	$788K-33.6%	$1.2M+12.1%	$1.1M+0.1%	$1.1M+84.1%	$574K-37.9%	$924K+13.0%	$818K
Current Assets	N/A	$779K-33.8%	$1.2M+12.3%	$1.0M+0.1%	$1.0M+86.1%	$562K-38.3%	$911K+13.2%	$805K
Cash & Equivalents	N/A	$198K-54.4%	$434K+29.9%	$334K-38.1%	$540K+167.3%	$202K-41.6%	$346K-0.9%	$349K
Inventory	N/A	$244K+3.0%	$237K+68.1%	$141K+7.6%	$131K+74.7%	$75K+4.2%	$72K+28.6%	$56K
Accounts Receivable	N/A	$252K-35.2%	$389K-17.9%	$474K+65.2%	$287K+59.4%	$180K-51.5%	$371K+24.5%	$298K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$7.1M+4.9%	$6.7M+9.0%	$6.2M+5.2%	$5.9M+21.3%	$4.8M+9.5%	$4.4M+20.0%	$3.7M
Current Liabilities	N/A	$3.1M-3.3%	$3.2M+236.8%	$938K-3.5%	$972K+12.2%	$866K-4.9%	$911K+24.3%	$733K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$6.3M-13.1%	-$5.5M-8.4%	-$5.1M-6.3%	-$4.8M-12.8%	-$4.3M-22.1%	-$3.5M-22.1%	-$2.9M
Retained Earnings	N/A	-$140.2M-0.6%	-$139.5M-0.3%	-$139.0M-0.2%	-$138.7M-0.4%	-$138.1M-0.6%	-$137.3M-0.5%	-$136.6M

PURE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.0M+20.4%	-$2.5M+22.8%	-$3.3M-35.6%	-$2.4M-107.2%	-$1.2M-274.4%	$669K
Capital Expenditures	N/A	N/A	$33K-59.3%	$81K-84.5%	$521K+798.3%	$58K
Free Cash Flow	N/A	N/A	-$3.3M-32.5%	-$2.5M-48.0%	-$1.7M-376.3%	$611K
Investing Cash Flow	N/A	N/A	-$33K+59.3%	-$81K+84.5%	-$521K-798.3%	-$58K
Financing Cash Flow	$2.0M+12.0%	$1.8M+75.9%	$1.0M-71.0%	$3.5M+1364.4%	$239K-91.6%	$2.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$606K0.0%	-$606K-142.4%	-$250K+45.2%	-$456K+10.9%	-$512K+5.9%	-$544K-8.2%	-$503K+15.2%	-$593K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$370K0.0%	$370K+5.7%	$350K+40.0%	$250K-70.6%	$850K+112.5%	$400K-20.0%	$500K0.0%	$500K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PURE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	59.3%+0.3pp	58.9%+7.0pp	51.9%-3.3pp	55.2%-1.0pp	56.1%-2.0pp	58.1%
Operating Margin	-103.4%+59.9pp	-163.2%+47.5pp	-210.7%-5.3pp	-205.4%-142.9pp	-62.5%-62.6pp	0.1%
Net Margin	-109.1%+62.2pp	-171.4%+40.3pp	-211.7%-19.1pp	-192.6%-129.8pp	-62.7%-62.8pp	0.1%
Return on Equity	N/A	N/A	N/A	-116.4%-31.3pp	-85.0%-85.1pp	0.1%
Return on Assets	-202.3%+160.3pp	-362.6%-186.5pp	-176.0%-81.7pp	-94.4%-29.1pp	-65.2%-65.3pp	0.1%
Current Ratio	0.37-0.6	1.00-1.6	2.56-1.8	4.39+1.4	2.96-2.4	5.39
Debt-to-Equity	-1.21+0.1	-1.26+5.6	-6.87-7.1	0.23-0.1	0.30+0.1	0.19
FCF Margin	N/A	N/A	-177.0%-39.1pp	-137.8%-92.2pp	-45.6%-54.5pp	8.8%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	60.6%+6.8pp	53.7%-9.9pp	63.6%+2.3pp	61.3%+3.5pp	57.9%-0.2pp	58.1%-0.5pp	58.6%+0.3pp	58.3%
Operating Margin	-93.5%+60.7pp	-154.2%-100.6pp	-53.6%-9.6pp	-44.0%+75.4pp	-119.4%+66.0pp	-185.4%-72.5pp	-113.0%+35.1pp	-148.1%
Net Margin	-109.9%+67.3pp	-177.2%-111.6pp	-65.6%-22.1pp	-43.5%+75.1pp	-118.6%+85.5pp	-204.1%-80.0pp	-124.1%+36.0pp	-160.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-99.6%-60.5pp	-39.1%-7.7pp	-31.4%+23.5pp	-54.9%+84.2pp	-139.0%-64.5pp	-74.6%+17.8pp	-92.4%
Current Ratio	N/A	0.26-0.1	0.37-0.7	1.12+0.0	1.08+0.4	0.65-0.4	1.00-0.1	1.10
Debt-to-Equity	N/A	-1.13+0.1	-1.210.0	-1.21+0.0	-1.22-0.1	-1.13+0.1	-1.26+0.0	-1.29
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$5.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.37), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cca Industries CAWW

$3.8M

Sentient Brands Hldgs Inc SNBH

$291K

Skinvisible SKVI

$1.3M

Naples Soap Company Ord Shs NASO

$659K

Bemax BMXC

$5.2M

Frequently Asked Questions

What is Pure Bioscience Inc's annual revenue?

Pure Bioscience Inc (PURE) reported $2.2M in total revenue for fiscal year 2025. This represents a 12.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pure Bioscience Inc's revenue growing?

Pure Bioscience Inc (PURE) revenue grew by 12.4% year-over-year, from $2.0M to $2.2M in fiscal year 2025.

Is Pure Bioscience Inc profitable?

No, Pure Bioscience Inc (PURE) reported a net income of -$2.4M in fiscal year 2025, with a net profit margin of -109.1%.

What is Pure Bioscience Inc's EBITDA?

Pure Bioscience Inc (PURE) had EBITDA of -$2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pure Bioscience Inc's gross margin?

Pure Bioscience Inc (PURE) had a gross margin of 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pure Bioscience Inc's operating margin?

Pure Bioscience Inc (PURE) had an operating margin of -103.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pure Bioscience Inc's net profit margin?

Pure Bioscience Inc (PURE) had a net profit margin of -109.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pure Bioscience Inc's operating cash flow?

Pure Bioscience Inc (PURE) generated -$2.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pure Bioscience Inc's total assets?

Pure Bioscience Inc (PURE) had $1.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Pure Bioscience Inc spend on research and development?

Pure Bioscience Inc (PURE) invested $316K in research and development during fiscal year 2025.

How many shares does Pure Bioscience Inc have outstanding?

Pure Bioscience Inc (PURE) had 112M shares outstanding as of fiscal year 2025.

What is Pure Bioscience Inc's current ratio?

Pure Bioscience Inc (PURE) had a current ratio of 0.37 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Pure Bioscience Inc's debt-to-equity ratio?

Pure Bioscience Inc (PURE) had a debt-to-equity ratio of -1.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pure Bioscience Inc's return on assets (ROA)?

Pure Bioscience Inc (PURE) had a return on assets of -202.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pure Bioscience Inc's cash runway?

Based on fiscal year 2025 data, Pure Bioscience Inc (PURE) had $434K in cash against an annual operating cash burn of $2.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Pure Bioscience Inc's debt-to-equity ratio negative or unusual?

Pure Bioscience Inc (PURE) has negative shareholder equity of -$5.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Pure Bioscience Inc's Piotroski F-Score?

Pure Bioscience Inc (PURE) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pure Bioscience Inc's earnings high quality?

Pure Bioscience Inc (PURE) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pure Bioscience Inc cover its interest payments?

Pure Bioscience Inc (PURE) has an interest coverage ratio of -7.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.